Standardized Ketogenic Dietary Preparation for Metabolic PET Imaging in Suspected and Known Cardiac Sarcoidosis

European Heart Journal - Imaging Methods and Practice Pub Date : 2024-05-09 DOI:10.1093/ehjimp/qyae037

E. Hutt, Ghazaleh Goldar, Wael A. Jaber, Paul C. Cremer

{"title":"Standardized Ketogenic Dietary Preparation for Metabolic PET Imaging in Suspected and Known Cardiac Sarcoidosis","authors":"E. Hutt, Ghazaleh Goldar, Wael A. Jaber, Paul C. Cremer","doi":"10.1093/ehjimp/qyae037","DOIUrl":null,"url":null,"abstract":"\n \n \n A major limitation of cardiac positron emission tomography (PET) with F18-fluorodeoxyglucose (F18-FDG) for the evaluation of cardiac sarcoidosis (CS) is associated with physiologic myocardial glucose uptake. The optimal dietary protocol to suppress physiologic myocardial F18-FDG uptake is not well-established. We aimed to evaluate the diagnostic performance of a novel dietary preparation using a ketone-based infant formula.\n \n \n \n Between 2018 and 2021, consecutive studies using a ketogenic dietary preparation were identified (n=198). The rate of non-diagnostic studies due to failure to suppress myocardial glucose was 7.1% (n= 14) with a similar incidence in diabetics (n= 6, 8.1%). Among studies reported to have no inflammation (N= 137), 130 studies (66%) had mean myocardial SUV less than or equal to mean blood pool SUV.\n \n \n \n Patient preparation with a ketone-based infant formula resulted in low rate of inappropriate myocardial glucose suppression in patients undergoing F18-FDG cardiac PET to evaluate cardiac sarcoidosis.\n","PeriodicalId":508944,"journal":{"name":"European Heart Journal - Imaging Methods and Practice","volume":" 32","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal - Imaging Methods and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjimp/qyae037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

A major limitation of cardiac positron emission tomography (PET) with F18-fluorodeoxyglucose (F18-FDG) for the evaluation of cardiac sarcoidosis (CS) is associated with physiologic myocardial glucose uptake. The optimal dietary protocol to suppress physiologic myocardial F18-FDG uptake is not well-established. We aimed to evaluate the diagnostic performance of a novel dietary preparation using a ketone-based infant formula. Between 2018 and 2021, consecutive studies using a ketogenic dietary preparation were identified (n=198). The rate of non-diagnostic studies due to failure to suppress myocardial glucose was 7.1% (n= 14) with a similar incidence in diabetics (n= 6, 8.1%). Among studies reported to have no inflammation (N= 137), 130 studies (66%) had mean myocardial SUV less than or equal to mean blood pool SUV. Patient preparation with a ketone-based infant formula resulted in low rate of inappropriate myocardial glucose suppression in patients undergoing F18-FDG cardiac PET to evaluate cardiac sarcoidosis.

查看原文本刊更多论文

用于疑似和已知心脏肉样瘤病代谢 PET 成像的标准化生酮饮食制剂

用 F18-氟脱氧葡萄糖（F18-FDG）进行心脏正电子发射断层扫描（PET）评估心脏肉样瘤病（CS）的主要局限性与生理性心肌葡萄糖摄取有关。抑制生理性心肌 F18-FDG 摄取的最佳饮食方案尚未确定。我们旨在评估一种使用酮基婴儿配方的新型饮食制剂的诊断性能。在 2018 年至 2021 年期间，我们确定了使用生酮饮食制剂的连续研究（n=198）。由于未能抑制心肌葡萄糖而导致的非诊断性研究的比例为 7.1%（n= 14），糖尿病患者的发生率与之相似（n= 6，8.1%）。在报告无炎症的研究中（N= 137），130 项研究（66%）的平均心肌 SUV 小于或等于平均血池 SUV。在接受 F18-FDG 心脏 PET 评估心脏肉样瘤病的患者中，使用酮基婴儿配方奶粉为患者做准备导致不适当的心肌葡萄糖抑制率较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Heart Journal - Imaging Methods and Practice

自引率

0.00%

发文量